Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

Trial Details

NCT ID

NCT06555133

Phase

PHASE2

Sponsor

Brown University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

yttrium-90 radioembolization

Locations (sample)

Providence, Rhode Island, United States|41.82399,-71.41283

Key Eligibility Criteria

Histologically confirmed diagnosis of colorectal adenocarcinoma
Surgically unresectable, liver-isolated or liver-dominant, RECIST measurable, metastatic disease
Age ≥18 years at the time of signing informed consent
ECOG performance status 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →